RetinalGenix Technologies

RTGN · OTC

$3.99+$0.00 (+0.00%)TodayMarket closed · Sep 24, 10:34 AM ET

No price history for this range.

About RTGN

RetinalGeniX Technologies, Inc. operates as a medical device company. The company is headquartered in Petaluma, California. The company went IPO on 2022-01-07. The firm's proprietary High-Resolution Retinal Imaging and DNA/RNA/GPS Pharmaco-Genetic Mapping technologies are designed to help prevent blindness by detecting initial physiological changes that could indicate future ocular and systemic diseases affecting neurodegenerative, cardiovascular, vascular and metabolic systems, as well as diabetic conditions, Alzheimer’s disease and Parkinson’s disease. Its RetinalCam is an in-home/remote location patient-activated monitoring and imaging device offering real-time communication and alerting system for physicians available 24/7. The company is also engaged in the development of its product candidates: RTG-2023 and RTG-2024. RTG-2023 for the treatment of dry age-related macular degeneration (dry AMD). RTG-2024 for the treatment of Alzheimer’s syndrome dementia.

Employees: 0
Headquarters: Petaluma, California
Listed: Jan 7, 2022
Sector: Health Care
Industry: Health Care Equipment & Supplies
Website: retinalgenix.com

Leadership

RetinalGenix Technologies executives
Name	Title	Since	Age
Jerry Katzman	—	2018	72
Dessislava Boneva	—	—	54
Herbert Gould	—	—	96
Vinay Mehindru	—	—	57

Similar companies

Companies in the same industry as RetinalGenix Technologies

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.